

Trudo Lemmens

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6760516/publications.pdf>

Version: 2024-02-01

52
papers

1,700
citations

430874

18
h-index

302126

39
g-index

54
all docs

54
docs citations

54
times ranked

1439
citing authors

#	ARTICLE	IF	CITATIONS
1	The Declaration of Helsinki. <i>BMJ: British Medical Journal</i> , 2007, 335, 624-625.	2.3	401
2	Research Ethics Recommendations for Whole-Genome Research: Consensus Statement. <i>PLoS Biology</i> , 2008, 6, e73.	5.6	212
3	The unintended consequences of COVID-19 vaccine policy: why mandates, passports and restrictions may cause more harm than good. <i>BMJ Global Health</i> , 2022, 7, e008684.	4.7	122
4	7th Revision of the Declaration of Helsinki: Good News for the Transparency of Clinical Trials. <i>Croatian Medical Journal</i> , 2009, 50, 105-110.	0.7	114
5	Ethics Review for Sale? Conflict of Interest and Commercial Research Review Boards. <i>Milbank Quarterly</i> , 2000, 78, 547-584.	4.4	80
6	Guinea Pigs on the payroll: The ethics of paying research subjects. <i>Accountability in Research</i> , 1999, 7, 3-20.	2.4	79
7	Justice for the Professional Guinea Pig. <i>American Journal of Bioethics</i> , 2001, 1, 51-53.	0.9	67
8	The social and cultural shaping of medical evidence: Case studies from pharmaceutical research and obstetric science. <i>Social Science and Medicine</i> , 2006, 62, 2694-2706.	3.8	66
9	Should assisted dying for psychiatric disorders be legalized in Canada?. <i>Cmaj</i> , 2016, 188, E337-E339.	2.0	63
10	The OHRP and SUPPORT â€” Another View. <i>New England Journal of Medicine</i> , 2013, 369, e3.	27.0	53
11	Legal Remedies for Medical Ghostwriting: Imposing Fraud Liability on Guest Authors of Ghostwritten Articles. <i>PLoS Medicine</i> , 2011, 8, e1001070.	8.4	52
12	Leopards in the Temple: Restoring Scientific Integrity to the Commercialized Research Scene. <i>Journal of Law, Medicine and Ethics</i> , 2004, 32, 641-657.	0.9	38
13	The Human Subjects Trade: Ethical and Legal Issues Surrounding Recruitment Incentives. <i>Journal of Law, Medicine and Ethics</i> , 2003, 31, 398-418.	0.9	33
14	Avoiding a Jekyll-And-Hyde Approach to the Ethics of Clinical Research and Practice. <i>American Journal of Bioethics</i> , 2002, 2, 14-17.	0.9	30
15	Should Society Allow Research Ethics Boards to Be Run As For-Profit Enterprises?. <i>PLoS Medicine</i> , 2006, 3, e309.	8.4	29
16	Structuring the Review of Human Genetics Protocols Part II: Diagnostic and Screening Studies. <i>IRB: Ethics & Human Research</i> , 1997, 19, 1.	0.8	25
17	Pharmaceutical Knowledge Governance: A Human Rights Perspective. <i>Journal of Law, Medicine and Ethics</i> , 2013, 41, 163-184.	0.9	24
18	Privatizing biomedical researchâ€”a 'third way'. <i>Nature Biotechnology</i> , 2008, 26, 31-36.	17.5	22

#	ARTICLE	IF	CITATIONS
19	Does the FDA have the authority to trump the Declaration of Helsinki?. <i>BMJ: British Medical Journal</i> , 2009, 338, b1559-b1559.	2.3	16
20	Niche Markets and Evidence Assessment in Transition: A Critical Review of Proposed Drug Reforms. <i>Medical Law Review</i> , 2014, 22, 200-220.	0.5	14
21	Access to information and the right to health: the human rights case for clinical trials transparency. <i>American Journal of Law and Medicine</i> , 2012, 38, 63-112.	0.2	12
22	Regulators, Pivotal Clinical Trials, and Drug Regulation in the Age of COVID-19. <i>International Journal of Health Services</i> , 2021, 51, 5-13.	2.5	11
23	“What About Your Genes?” Ethical, Legal, and Policy Dimensions of Genetics in the Workplace. <i>Politics and the Life Sciences</i> , 1997, 16, 57-75.	0.7	10
24	Noninstitutional Commercial Review Boards in North America. <i>IRB: Ethics & Human Research</i> , 2001, 23, 1.	0.8	9
25	Prospective registration and results disclosure of clinical trials in the Americas: a roadmap toward transparency. <i>Revista Panamericana De Salud Publica/Pan American Journal of Public Health</i> , 2011, 30, 87-96.	1.1	9
26	Piercing the Veil of Corporate Secrecy about Clinical Trials. <i>Hastings Center Report</i> , 2004, 34, 14.	1.0	8
27	Why the Shift? Taking a Closer Look at the Growing Interest in Niche Markets and Personalized Medicine. <i>World Medical and Health Policy</i> , 2015, 7, 3-27.	1.6	8
28	Federal regulation of REB review of clinical trials: a modest but easy step towards an accountable REB review structure in Canada. <i>Health Law Review</i> , 2005, 13, 39-50.	0.1	8
29	Towards the right to be killed?: Treatment refusal, assisted suicide and euthanasia in the United States and Canada. <i>British Medical Bulletin</i> , 1996, 52, 341-353.	6.9	7
30	Confronting the conflict of interest crisis in medical research. <i>Monash Bioethics Review</i> , 2004, 23, 19-40.	0.8	7
31	Title is missing!. <i>European Journal of Health Law</i> , 2000, 7, 265-292.	0.2	7
32	Regulating the Market in Human Research Participants. <i>PLoS Medicine</i> , 2006, 3, e330.	8.4	6
33	Transparency of Biobank Access in Canada: An Assessment of Industry Access and the Availability of Information on Access Policies and Resulting Research. <i>Journal of Empirical Research on Human Research Ethics</i> , 2017, 12, 310-325.	1.3	6
34	Integrating Values in Risk Analysis of Biomedical Research: The Case for Regulatory and Law Reform. <i>University of Toronto Law Journal</i> , 2004, 54, 249-290.	0.2	5
35	Decreasing the Data Deficit: Improving Post-Market Surveillance in Pharmaceutical Regulation. <i>McGill Law Journal</i> , 0, 59, 943-988.	0.1	5
36	The institutional workers of biomedical science: Legitimizing academic entrepreneurship and obscuring conflicts of interest. <i>Science and Public Policy</i> , 2018, 45, 404-415.	2.4	5

#	ARTICLE	IF	CITATIONS
37	When a Theoretical Commitment to Broad Physician Aid-in-Dying Faces the Reality of Its Implementation. <i>American Journal of Bioethics</i> , 2019, 19, 65-68.	0.9	5
38	Financial conflict of interest in medical research. , 2008, , 222-230.		4
39	Global Health Challenges and the Role of Law. <i>Journal of Law, Medicine and Ethics</i> , 2013, 41, 9-15.	0.9	4
40	CIOMS' Placebo Rule and the Promotion of Negligent Medical Practice. <i>European Journal of Health Law</i> , 2004, 11, 153-174.	0.2	3
41	How Can Journals Respond to Threats of Libel Litigation?. <i>PLoS Medicine</i> , 2014, 11, e1001615.	8.4	3
42	Clinical trial transparency in the Americas: the need to coordinate regulatory spheres. <i>BMJ: British Medical Journal</i> , 2018, 362, k2493.	2.3	3
43	Private Parties, Public Duties?. , 1999, , 31-39.		2
44	Currents in Contemporary Ethics. <i>Journal of Law, Medicine and Ethics</i> , 2004, 32, 365-368.	0.9	2
45	Research Ethics Boards: Reply from Trudo Lemmens and Carl Elliott. <i>PLoS Medicine</i> , 2006, 3, e471.	8.4	2
46	Regulation of health professions in Ontario: self-regulation with statutory- based public accountability. <i>Revista De Direito Sanitario</i> , 2019, 19, 124-204.	0.1	2
47	Conflict of Interest and Commercialization of Biomedical Research. , 1999, , 79-99.		2
48	Euthanasia and the Good Life. <i>Perspectives in Biology and Medicine</i> , 1995, 39, 15-27.	0.5	1
49	In the Name of National Security: Lessons from the Final Report on the Human Radiation Experiments. <i>European Journal of Health Law</i> , 1999, 6, 7-23.	0.2	1
50	Investigating Research and Accessing Reproductive Material. <i>Journal of Bioethical Inquiry</i> , 2014, 11, 11-19.	1.5	1
51	Governance of conflicts of interest in postmarketing surveillance research and the Canadian Drug Safety and Effectiveness Network. <i>Open Medicine</i> , 2010, 4, e123-8.	1.5	1
52	Legal remedies for medical ghostwriting: Imposing fraud liability on guest authors of ghostwritten articles. <i>Medical Writing</i> , 2013, 22, 264-271.	0.1	0